Clinical Trials Logo

Clinical Trial Summary

Prospective exploratory study specifically investigating the role of 11C-Methionine PET/CT imaging in patients affected by Malignant Pleural Mesothelioma (MPM) and candidate to pleurodesis.


Clinical Trial Description

This is a single-center, open-label study, lasting 36 months including an estimated period of 24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at the end of three cycles of chemotherapy.

A minimum number of 20 patients will be considered for the analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02519049
Study type Observational
Source Istituto Clinico Humanitas
Contact
Status Completed
Phase
Start date September 2014
Completion date December 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06057935 - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Phase 2
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Terminated NCT02357147 - Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Phase 2
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Completed NCT02303899 - Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma Phase 2
Recruiting NCT05380713 - ......SMARTEST Trial...... Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT05568680 - SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma Phase 1
Terminated NCT03502746 - Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Phase 2
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Recruiting NCT06251310 - SW-682 in Advanced Solid Tumors Phase 1
Recruiting NCT05944237 - HTL0039732 in Participants With Advanced Solid Tumours Phase 1/Phase 2
Active, not recruiting NCT05455424 - Niraparib Efficacy in Patient With Unresectable Mesothelioma Phase 2
Recruiting NCT05324436 - A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Active, not recruiting NCT03654833 - Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Phase 2
Recruiting NCT05136677 - A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants Phase 2
Not yet recruiting NCT05698238 - Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours Phase 1
Not yet recruiting NCT05188859 - First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma Phase 2